<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00212017</url>
  </required_header>
  <id_info>
    <org_study_id>CSSCJ-3</org_study_id>
    <secondary_id>UMIN_ID:C000000090</secondary_id>
    <nct_id>NCT00212017</nct_id>
  </id_info>
  <brief_title>Assessment of an Alpha-glucosidase Inhibitor to Block Cardiac Events in Patients With MI and IGT</brief_title>
  <official_title>The Japan Working Group for the Assessment That the Alpha-glucosidase Inhibitor Blocks Cardiac Events in Patients With Myocardial Infarction and IGT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cerebral and Cardiovascular Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labor and Welfare (Japan)</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>National Cerebral and Cardiovascular Center</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate whether an alpha-glucosidase inhibitor, a drug for
      the suppression of postprandial hyperglycemia, could reduce the recurrence of myocardial
      infarction in patients with impaired glucose tolerance (IGT) and old myocardial infarction.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Type 2 diabetes mellitus is a well-established risk factor for coronary heart disease and
      atherosclerotic change in the coronary artery develops subclinically in a state of impaired
      glucose tolerance (IGT). Recently postprandial hyperglycemia as a feature of impaired glucose
      tolerance is recognized as a significant risk factor for coronary heart disease. So we
      designed a prospective randomized multi-center trial named Assessment of an
      α-glucosidase-inhibitor to Block Cardiac Events in Patients With Myocardial Infarction and
      IGT (ABC study) to evaluate whether an α-Glucosidase Inhibitor, a drug for the suppression of
      postprandial hyperglycemia, could reduce the recurrence of myocardial infarction in patients
      with IGT and old myocardial infarction.

      100 hospitals will participate in the ABC study. Patients with IGT who have a history of
      prior myocardial infarction are randomly allocated to receive α-Glucosidase Inhibitor
      (voglibose) or a standard diet and exercise treatment. The number of patients to be recruited
      is 3000 and this study will continue for at least 2 years. The primary end-points are:

        1. cardiovascular mortality and

        2. hospitalization for cardiovascular events.

      Effects in suppression of new diabetes development will also be evaluated.

      We should recognize IGT as an important therapeutic target to decrease the recurrence of
      cardiovascular events. The ABC study, a large scale multi-center trial in Japan, will provide
      us with new evidence on how to treat IGT patients with prior myocardial infarction.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    We obtained the final results due to the interim analysis.
  </why_stopped>
  <start_date type="Actual">April 2005</start_date>
  <completion_date type="Actual">August 2017</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Prospective, randomised, open, blinded-endpoint study</intervention_model_description>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Single (Outcomes Assessor)</masking>
    <masking_description>This is an open and blinded-endpoint study</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>the time till the first cardiovascular composite endpoint of death from cardiovascular death, and hospitalization due to nonfatal myocardial infarction, nonfatal unstable angina[16], nonfatal stroke, or treatment with coronary revascularisation</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>the time till the first cardiovascular composite endpoint of death from the time till the first cardiovascular composite endpoint of death from cardiovascular death, and hospitalization due to nonfatal myocardial infarction, nonfatal unstable angina[16], nonfatal stroke, or treatment with coronary revascularisation</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>All cause mortality</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>All cause death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to coronary artery disease</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>Hospitalization due to coronary artery disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression of IGT to diabetes</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>Progression of IGT to diabetes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Development or deterioration of either hypertension or hyperlipidemia</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>Development or deterioration of either hypertension or hyperlipidemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Deterioration of renal function</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>Deterioration of renal function</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to cerebrovascular disease</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>Hospitalization due to cerebrovascular disease</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospitalization due to heart failure</measure>
    <time_frame>May 2005 and June 2012</time_frame>
    <description>Hospitalization due to heart failure</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">3000</enrollment>
  <condition>Impaired Glucose Tolerance</condition>
  <condition>Myocardial Infarction</condition>
  <arm_group>
    <arm_group_label>the voglibose group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants in the voglibose group were administered a voglibose tablet (0.2 mg) three times daily before meals.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>the control group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Participants assigned to the control group were treated only with diet and exercise therapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>voglibose</intervention_name>
    <arm_group_label>the voglibose group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>diet and exercise therapy</intervention_name>
    <arm_group_label>the control group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Impaired glucose tolerance

          2. History of myocardial infarction

        Exclusion Criteria:

          1. Type I diabetes

          2. History of coronary artery bypass graft

          3. Severe liver and/or kidney dysfunction

          4. History of allergic response to drugs

          5. Arteriosclerosis obliterans
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Masafumi Kitakaze, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>National Cerebral and Cardiovascular Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cardiovascular Center</name>
      <address>
        <city>Suita</city>
        <state>Osaka</state>
        <zip>565-8565</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <results_reference>
    <citation>Asakura M, Kim J, Asanuma H, Hamasaki T, Tsukahara K, Higashino Y, Ishikawa T, Nakama Y, Koba S, Maruyama Y, Tsujimoto M, Himeno H, Ohkusa T, Fujino S, Shimizu M, Endo T, Yoda S, Muroya T, Murohara T, Ohte N, Suzuki H, Kohno T, Fukui K, Shiono T, Takase H, Uzui H, Nagai Y, Hashimoto Y, Ikeda S, Mizuno S, Tamita K, Fujita M, Satake K, Kinoshita Y, Nunohiro T, Sakagami S, Higaki J, Morii I, Sawada R, Hiasa Y, Shigemasa T, Nakahama M, Sata M, Doi O, Ueda T, Yamada T, Yamanouchi T, Yamaguchi H, Morita Y, Hayashi H, Kitakaze M; ABC investigators. Does Treatment of Impaired Glucose Tolerance Improve Cardiovascular Outcomes in Patients with Previous Myocardial Infarction? Cardiovasc Drugs Ther. 2017 Aug;31(4):401-411. doi: 10.1007/s10557-017-6740-3.</citation>
    <PMID>28779371</PMID>
  </results_reference>
  <verification_date>August 2018</verification_date>
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2005</study_first_posted>
  <last_update_submitted>August 20, 2018</last_update_submitted>
  <last_update_submitted_qc>August 20, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">August 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>National Cerebral and Cardiovascular Center</investigator_affiliation>
    <investigator_full_name>Masafumi Kitakaze</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <keyword>IGT</keyword>
  <keyword>Myocardial Infarction</keyword>
  <keyword>alpha-glucosidase inhibitor</keyword>
  <keyword>re-infarction prevention</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Myocardial Infarction</mesh_term>
    <mesh_term>Glucose Intolerance</mesh_term>
    <mesh_term>Infarction</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Voglibose</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

